PDF herunterladen
Nervenheilkunde 2023; 42(07/08): 450-458
DOI: 10.1055/a-2101-9358
Schwerpunkt

Psychedelikagestützte Psychotherapie in der Behandlung depressiver Störungen

Ein Blick auf die Vergangenheit, den Stand der Forschung und die ZukunftPsychedelics-assisted psychotherapy for the treatment of depressionA view at the past, the current state of research, and an outlook
Lilith Becher
1   Klinik für Psychiatrie und Psychotherapie, Campus Charité Mitte, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin
,
Federico Nanni
1   Klinik für Psychiatrie und Psychotherapie, Campus Charité Mitte, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin
,
Michael Koslowski
1   Klinik für Psychiatrie und Psychotherapie, Campus Charité Mitte, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin
2   Aix Marseille Univ, IMERA, Marseille, Frankreich
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

ZUSAMMENFASSUNG

In den letzten Jahren wurde ein Anstieg depressiver Erkrankungen innerhalb der deutschen Bevölkerung verzeichnet [1]. Dabei sprechen ca. 30 % der Patienten nicht ausreichend auf die Behandlung mit verschiedenen Antidepressiva an und gelten somit als therapieresistent [2]. Psychedelika wie Psilocybin stellen einen vielversprechenden Therapieansatz in der Behandlung der Depression dar. Der Einsatz von Psychedelika in Therapie und Forschung wurde Anfang der 1970er-Jahre durch die Eingruppierung als Betäubungsmittel stark erschwert und ist erst in den 1990er-Jahren wieder aufgenommen worden.

In diesem Artikel wird der Stand der Forschung zur psychedelikaassistierten Psychotherapie vorgestellt. Ein besonderes Augenmerk wird dabei auf die Forschung zu psychedelikagestützter Psychotherapie bei depressiven Störungen gelegt, gefolgt von einem Ausblick.

ABSTRACT

Over the past years, the number of depressive disorders amongst the German population has risen [1]. Approximately 30 % of patients treated with antidepressants do not show adequate treatment response and are diagnosed as therapy-resistant [2]. Psychedelics such as psilocybin represent a promising therapeutic approach in the treatment of depression. Treatment and clinical research with psychedelics was hampered since the 1970ies due to classification as schedule-I-substances, and was resumed only from the 1990ies on.

This article reviews the state of research on psychedelic-assisted therapy. Special attention is given to research on psychedelic-assisted psychotherapy for depression, followed by an outlook.

Schlüsselwörter

Therapieresistente Depression - psychedelikaassistierte Psychotherapie - psilocybingestützte Psychotherapie

Key words

Therapy-resistant depression - psychedelic-assisted psychotherapy - psilocybin


Publikationsverlauf

Artikel online veröffentlicht:
07. Juli 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Busch M, Maske U, Ryl L. et al Prävalenz von depressiver Symptomatik und diagnostizierter Depression bei Erwachsenen in Deutschland. 2013. Berlin: RKI; DOI: 10.1007/s00103-013-1688-3
    CrossrefGoogle Scholar
  • 2 Ludwig W-D, Mühlbauer B, Seifert R. Arzneiverordnungs-Report 2021. Berlin: Springer; 2021
    CrossrefGoogle Scholar
  • 3 Nichols DE. Chemistry and structure-activity relationships of psychedelics. Behavioral Neurobiology of Psychedelic Drugs 2018: 1-43
    PubMedGoogle Scholar
  • 4 Amoroso T, Workman M. Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: a preliminary meta-analysis and comparison to prolonged exposure therapy. Journal of Psychopharmacology 2016; 30: 595-600
    CrossrefPubMedGoogle Scholar
  • 5 Papakostas GI, Salloum NC, Hock RS. et al Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. The Journal of clinical psychiatry 2020; 81: 6603
    CrossrefPubMedGoogle Scholar
  • 6 Bisbee CC, Bisbee P, Dyck E. et al Psychedelic Prophets: The Letters of Aldous Huxley and Humphry Osmond. New York: McGill-Queen’s Press-MQUP; 2018
    CrossrefGoogle Scholar
  • 7 Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. Journal of psychopharmacology 2008; 22: 603-620
    CrossrefPubMedGoogle Scholar
  • 8 Ulrich RF, Patten BM. The rise, decline, and fall of LSD. Perspectives in Biology and Medicine 1991; 34: 561-578
    CrossrefPubMedGoogle Scholar
  • 9 Grinspoon L, Bakalar JB. Psychedelic drugs reconsidered. New York: Basic Books; 1979
    Google Scholar
  • 10 Sandison RA. Psychological aspects of the LSD treatment of the neuroses. Journal of Mental Science 1954; 100: 508-515
    CrossrefPubMedGoogle Scholar
  • 11 Chwelos N, Blewett D, Smith CM. et al Use of d-lysergic acid diethylamide in the treatment of alcoholism. Quarterly journal of studies on alcohol 1959; 20: 577-590
    CrossrefPubMedGoogle Scholar
  • 12 Ludwig A, Levine J, Stark L. et al A clinical study of LSD treatment in alcoholism. American Journal of Psychiatry 1969; 126: 59-69
    CrossrefPubMedGoogle Scholar
  • 13 Kurland A, Savage C, Pahnke WN. et al LSD in the treatment of alcoholics. Pharmacopsychiatry 1971; 04: 83-94
    Artikel in Thieme ConnectGoogle Scholar
  • 14 Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study. Archives of General Psychiatry 1973; 28: 808-814
    CrossrefPubMedGoogle Scholar
  • 15 Savage C. Lysergic acid diethylamide (LSD-25) A clinical-psychological study. American Journal of Psychiatry 1952; 108: 896-900
    CrossrefPubMedGoogle Scholar
  • 16 Fernberger SW. Further observations on peyote intoxication. The Journal of Abnormal and Social Psychology 1932; 26: 367
    CrossrefGoogle Scholar
  • 17 Fernberger SW. Observations on Taking Peyote”(Anhalonium Lewinii)”. The American Journal of Psychology 1923; 34: 267-270
    CrossrefGoogle Scholar
  • 18 Guttmann E, Maclay W. Mescalin and depersonalization: therapeutic experiments. Journal of Neurology and Psychopathology 1936; 16: 193
    CrossrefPubMedGoogle Scholar
  • 19 Hofmann A. Psychotomimetic drugs. Acta physiologica et pharmacologica Neerlandica 1959; 08: 240-258
    Google Scholar
  • 20 Aresin L. Modellpsychosen. Psychiatrie, Neurologie und medizinische Psychologie 1960; 12: 94-99
    PubMedGoogle Scholar
  • 21 Aday JS, Bloesch EK, Davoli CC. Beyond LSD: a broader psychedelic zeitgeist during the early to mid-20th century. Journal of Psychoactive Drugs 2019; 51: 210-217
    CrossrefPubMedGoogle Scholar
  • 22 Johansen P-Ø, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of psychopharmacology 2015; 29: 270-279
    CrossrefPubMedGoogle Scholar
  • 23 Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A. et al Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998; 09: 3897-3902
    CrossrefPubMedGoogle Scholar
  • 24 Strassman RJ, Qualls CR. Dose-response study of N, N-dimethyltryptamine in humans: I. Neuroendocrine, autonomic, and cardiovascular effects. Archives of general psychiatry 1994; 51: 85-97
    CrossrefPubMedGoogle Scholar
  • 25 Strassman RJ, Qualls CR, Uhlenhuth EH. et al Dose-response study of N, N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale. Archives of general psychiatry 1994; 51: 98-108
    CrossrefPubMedGoogle Scholar
  • 26 Griffiths RR, Richards WA, McCann U. et al Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 2006; 187: 268-283
    CrossrefPubMedGoogle Scholar
  • 27 Hasler F, Grimberg U, Benz MA. et al Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study. Psychopharmacology 2004; 172: 145-156
    CrossrefPubMedGoogle Scholar
  • 28 Grob CS, Danforth AL, Chopra GS. et al Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of general psychiatry 2011; 68: 71-78
    CrossrefPubMedGoogle Scholar
  • 29 Ross S, Bossis A, Guss J. et al Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology 2016; 30: 1165-1180
    CrossrefPubMedGoogle Scholar
  • 30 Griffiths RR, Johnson MW, Carducci MA. et al Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology 2016; 30: 1181-1197
    CrossrefPubMedGoogle Scholar
  • 31 Gasser P, Holstein D, Michel Y. et al Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of nervous and mental disease 2014; 202: 513
    CrossrefPubMedGoogle Scholar
  • 32 Bogenschutz MP, Ross S. Therapeutic applications of classic hallucinogens. Behavioral neurobiology of psychedelic drugs 2018: 361-391
    PubMedGoogle Scholar
  • 33 Koslowski M, Johnson MW, Gründer G. et al Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. Current Addiction Reports 2022: 1-11
    PubMedGoogle Scholar
  • 34 Horton DM, Morrison B, Schmidt J. Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy. American journal of psychotherapy 2021; 74: 140-149
    CrossrefPubMedGoogle Scholar
  • 35 Johnson MW, Garcia-Romeu A, Cosimano MP. et al Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of psychopharmacology 2014; 28: 983-992
    CrossrefPubMedGoogle Scholar
  • 36 Bogenschutz MP, Forcehimes AA, Pommy JA. et al Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of psychopharmacology 2015; 29: 289-299
    CrossrefPubMedGoogle Scholar
  • 37 Passie T, Seifert J, Schneider U. et al The pharmacology of psilocybin. Addiction biology 2002; 07: 357-364
    CrossrefPubMedGoogle Scholar
  • 38 Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug metabolism reviews 2017; 49: 84-91
    CrossrefPubMedGoogle Scholar
  • 39 Hasler F, Bourquin D, Brenneisen R. et al Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharmaceutica Acta Helvetiae 1997; 72: 175-184
    CrossrefPubMedGoogle Scholar
  • 40 Furukawa TA, Cipriani A, Cowen PJ. et al Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. The Lancet Psychiatry 2019; 06: 601-609
    CrossrefPubMedGoogle Scholar
  • 41 Carhart-Harris RL, Bolstridge M, Rucker J. et al Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry 2016; 03: 619-627
    CrossrefPubMedGoogle Scholar
  • 42 Davis AK, Xin Y, Sepeda ND. et al Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chronic Stress 2021; 5: 24705470211035607
    Google Scholar
  • 43 Gukasyan N, Davis AK, Barrett FS. et al Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. Journal of Psychopharmacology 2022; 36: 151-158
    CrossrefPubMedGoogle Scholar
  • 44 Sanches RF, de Lima Osório F, Dos Santos RG. et al Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. Journal of clinical psychopharmacology 2016; 36: 77-81
    CrossrefPubMedGoogle Scholar
  • 45 Palhano-Fontes F, Barreto D, Onias H. et al Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological medicine 2019; 49: 655-663
    CrossrefPubMedGoogle Scholar
  • 46 Carhart-Harris R, Giribaldi B, Watts R. et al Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine 2021; 384: 1402-1411
    CrossrefPubMedGoogle Scholar
  • 47 Nayak SM, Bari BA, Yaden DB. et al A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression. Psychedelic Medicine 2023; 01: 18-26
    CrossrefPubMedGoogle Scholar
  • 48 Goodwin GM, Aaronson ST, Alvarez O. et al Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine 2022; 387: 1637-1648
    CrossrefPubMedGoogle Scholar
  • 49 Ko K, Knight G, Rucker JJ. et al Psychedelics, mystical experience, and therapeutic efficacy: a systematic review. Frontiers in psychiatry 2022: 13
    PubMedGoogle Scholar
  • 50 Mueller F, Lenz C, Dolder P. et al Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Translational psychiatry 2017; 07: e1084-e1084
    CrossrefPubMedGoogle Scholar
  • 51 Kraehenmann R, Preller KH, Scheidegger M. et al Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biological psychiatry 2015; 78: 572-581
    CrossrefPubMedGoogle Scholar
  • 52 Kraehenmann R. Dreams and psychedelics: neurophenomenological comparison and therapeutic implications. Current neuropharmacology 2017; 15: 1032-1042
    CrossrefPubMedGoogle Scholar
  • 53 Broyd SJ, Demanuele C, Debener S. et al Default-mode brain dysfunction in mental disorders: a systematic review. Neuroscience & biobehavioral reviews 2009; 33: 279-296
    CrossrefPubMedGoogle Scholar
  • 54 Carhart-Harris RL, Erritzoe D, Williams T. et al Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences 2012; 109: 2138-2143
    CrossrefPubMedGoogle Scholar
  • 55 Preller KH, Burt JB, Ji JL. et al Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife 2018; 07: e35082
    CrossrefPubMedGoogle Scholar
  • 56 Vargas MV, Dunlap LE, Dong C. et al Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 2023; 379: 700-706
    CrossrefPubMedGoogle Scholar
  • 57 Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology 2015; 29: 1182-1190
    CrossrefPubMedGoogle Scholar
  • 58 Carhart-Harris RL, Bolstridge M, Day CM. et al Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 2018; 235: 399-408
    CrossrefPubMedGoogle Scholar
  • 59 Davis AK, So S, Lancelotta R. et al 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American journal of drug and alcohol abuse 2019; 45: 161-169
    CrossrefPubMedGoogle Scholar
  • 60 Mertens LJ, Koslowski M, Betzler F. et al Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE)–Rationale and study design. Neuroscience Applied 2022; 01: 100104
    CrossrefGoogle Scholar
  • 61 Schlag AK, Aday J, Salam I. et al Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology 2022; 36: 258-272
    CrossrefPubMedGoogle Scholar
  • 62 Breeksema JJ, Kuin BW, Kamphuis J. et al Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. Journal of Psychopharmacology 2022; 36: 1100-1117
    CrossrefPubMedGoogle Scholar
  • 63 Halpern JH, Lerner AG, Passie T. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Behavioral neurobiology of psychedelic drugs 2018: 333-360
    PubMedGoogle Scholar
  • 64 Vis PJ, Goudriaan AE, Ter Meulen BC. et al On Perception and Consciousness in HPPD: A Systematic Review. Frontiers in Neuroscience 2021; 15: 675768
    CrossrefPubMedGoogle Scholar
  • 65 Krebs TS, Johansen P-Ø.. Psychedelics and mental health: a population study. PloS one 2013; 08: e63972
    CrossrefPubMedGoogle Scholar
  • 66 Dos Santos RG, Bouso JC, Hallak JE. Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. Therapeutic advances in psychopharmacology 2017; 07: 141-157
    CrossrefPubMedGoogle Scholar
  • 67 Gashi L, Sandberg S, Pedersen W. Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences. International Journal of Drug Policy 2021; 87: 102997
    CrossrefPubMedGoogle Scholar
  • 68 Hendricks PS, Thorne CB, Clark CB. et al Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology 2015; 29: 280-288
    CrossrefPubMedGoogle Scholar
  • 69 Zeifman RJ, Singhal N, Breslow L. et al On the relationship between classic psychedelics and suicidality: a systematic review. ACS Pharmacology & Translational Science 2021; 04: 436-451
    CrossrefPubMedGoogle Scholar
  • 70 Search of: Psychedelics | Recruiting NyR, Active, Not Recruiting, Enrolling by Invitation Studies | Depression – List Results – ClinicalTrials.gov, n.d.-b. clinicaltrails.gov
  • 71 Mertens LJ, Preller KH. Classical psychedelics as therapeutics in psychiatry–current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders. Pharmacopsychiatry 2021; 54: 176-190
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 72 Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. The American journal of drug and alcohol abuse 2017; 43: 55-60
    CrossrefPubMedGoogle Scholar
  • 73 Osório FdL, Sanches RF, Macedo LR. et al Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Brazilian Journal of Psychiatry 2015; 37: 13-20
    CrossrefPubMedGoogle Scholar
  • 74 Chuang-Stein C, Kirby S. The shrinking or disappearing observed treatment effect. Pharmaceutical Statistics 2014; 13: 277-280
    CrossrefPubMedGoogle Scholar
  • 75 Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. The Lancet 2010; 376: 1558-1565
    CrossrefPubMedGoogle Scholar
  • 76 Zeifman RJ, Wagner AC, Watts R. et al Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. Frontiers in psychiatry 2020: 782
    PubMedGoogle Scholar
  • 77 Kelly JR, Gillan CM, Prenderville J. et al Psychedelic therapy’s transdiagnostic effects: a research domain criteria (RDoC) perspective. Frontiers in psychiatry 2021: 2295
    PubMedGoogle Scholar
  • 78 Wolff M, Evens R, Mertens LJ. et al Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance. Frontiers in psychiatry 2020: 5
    PubMedGoogle Scholar